Crescent Innovations to Divest Osteoarthritis Treatment Technology

Crescent Innovations announced the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.

PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease. PgGA, while polyanionic like the current state of the art OA...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us